Benzinga’s Top Pre-Market NASDAQ Losers (MNTA, WERN, NVDA, ARMH)

Momenta Pharmaceuticals Inc MNTA dipped 4.17% to $25.02 in the pre-market session. Momenta has received approval from the Food and Drug Administration (FDA) to market a generic version of Sanofi's blood-thinner drug, Lovenox. Werner Enterprises Inc WERN lost 2.04% to $23.55 in the pre-market session. Analysts at Deutsche Bank downgraded WERN from “buy” to “hold.” NVIDIA Corporation NVDA fell 1.42% to $10.40 in the pre-market session. Rambus Inc RMBS had won its fight against NVDA and other companies yesterday after the trade panel agreed that RMBS’ patents were getting infringed. NVDA has, however, decided to appeal against the decision. ARM Holdings Plc ARMH slipped 1.20% to $15.70 in pre-market trading. ARMH has reported better-than-expected Q2 earnings. Read more from Benzinga's Company news.